S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:ORGS

Orgenesis (ORGS) Price Target & Analyst Ratings

$1.22
0.00 (0.00%)
(As of 03:59 PM ET)
Compare
Today's Range
$1.18
▼
$1.31
50-Day Range
$1.01
▼
$1.43
52-Week Range
$0.98
▼
$2.70
Volume
45,471 shs
Average Volume
60,239 shs
Market Capitalization
$34.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Orgenesis Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$6.00
391.80% Upside
High Prediction$6.00
Average Prediction$6.00
Low Prediction$6.00
TypeCurrent
5/30/22 to 5/30/23		1 Month Ago
4/30/22 to 4/30/23		3 Months Ago
3/1/22 to 3/1/23		1 Year Ago
5/30/21 to 5/30/22
Consensus Rating
Buy
Buy
N/AN/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
 N/A N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
 N/A N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
 N/A N/A
Consensus Price Target$6.00$6.00N/AN/A
Predicted Upside391.80% Upside319.58% UpsideN/AN/A
Get Orgenesis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.


ORGS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ORGS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Orgenesis Stock vs. The Competition

TypeOrgenesisMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside385.83% Upside1,318.13% Upside197.10% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/22/2023Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$6.00+319.58%
(Data available from 5/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ORGS Price Target - Frequently Asked Questions

What is Orgenesis's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Orgenesis stock is Buy based on the current 1 buy rating for ORGS. The average twelve-month price prediction for Orgenesis is $6.00 with a high price target of $6.00 and a low price target of $6.00. Learn more on ORGS's analyst rating history.

Do Wall Street analysts like Orgenesis more than its competitors?

Analysts like Orgenesis more than other Medical companies. The consensus rating score for Orgenesis is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how ORGS compares to other companies.

Does Orgenesis's stock price have much upside?

According to analysts, Orgenesis's stock has a predicted upside of 319.58% based on their 12-month price targets.

What analysts cover Orgenesis?

Orgenesis has been rated by Benchmark in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ORGS) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -